Cargando…
Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin
Erlotinib belongs to the targeted cancer treatments acting through epidermal growth factor receptor inhibition. Papulopustular eruption is the most common cutaneous toxicity. The pathogenesis of the rash is not clear. There is no consensus on treatment. In this report, we describe a 73-year-old fema...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900010/ https://www.ncbi.nlm.nih.gov/pubmed/27298507 http://dx.doi.org/10.4103/0253-7613.182887 |
_version_ | 1782436568448892928 |
---|---|
author | Akoglu, Gulsen Yavuz, Sibel Orhun Metin, Ahmet |
author_facet | Akoglu, Gulsen Yavuz, Sibel Orhun Metin, Ahmet |
author_sort | Akoglu, Gulsen |
collection | PubMed |
description | Erlotinib belongs to the targeted cancer treatments acting through epidermal growth factor receptor inhibition. Papulopustular eruption is the most common cutaneous toxicity. The pathogenesis of the rash is not clear. There is no consensus on treatment. In this report, we describe a 73-year-old female patient who was referred to our outpatient clinic for evaluation and treatment of a widespread acneiform eruption. She was put on erlotinib therapy for 3 months for the treatment of lung adenocarcinoma. The patient has developed nonpruritic papules and pustules widespread over the body except the face for the past 2 weeks. Bacterial culture obtained from a pustule on the back grew methicillin-sensitive Staphylococcus aureus (SA). Histopathological examination of a papule demonstrated vacuolar degeneration of basal layer, prominent walls of vessels, a mixed infiltration of eosinophils, and lymphocytes and erythrocyte extravasation. The eruption was successfully treated with two weekly pulses of azithromycin 500 mg for 3 consecutive days. This case demonstrated that erlotinib may cause purpuric papular eruption secondarily infected with SA. Routine bacterial culture should be performed from pustules before any treatment. |
format | Online Article Text |
id | pubmed-4900010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-49000102016-06-13 Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin Akoglu, Gulsen Yavuz, Sibel Orhun Metin, Ahmet Indian J Pharmacol Drug Watch Erlotinib belongs to the targeted cancer treatments acting through epidermal growth factor receptor inhibition. Papulopustular eruption is the most common cutaneous toxicity. The pathogenesis of the rash is not clear. There is no consensus on treatment. In this report, we describe a 73-year-old female patient who was referred to our outpatient clinic for evaluation and treatment of a widespread acneiform eruption. She was put on erlotinib therapy for 3 months for the treatment of lung adenocarcinoma. The patient has developed nonpruritic papules and pustules widespread over the body except the face for the past 2 weeks. Bacterial culture obtained from a pustule on the back grew methicillin-sensitive Staphylococcus aureus (SA). Histopathological examination of a papule demonstrated vacuolar degeneration of basal layer, prominent walls of vessels, a mixed infiltration of eosinophils, and lymphocytes and erythrocyte extravasation. The eruption was successfully treated with two weekly pulses of azithromycin 500 mg for 3 consecutive days. This case demonstrated that erlotinib may cause purpuric papular eruption secondarily infected with SA. Routine bacterial culture should be performed from pustules before any treatment. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4900010/ /pubmed/27298507 http://dx.doi.org/10.4103/0253-7613.182887 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Drug Watch Akoglu, Gulsen Yavuz, Sibel Orhun Metin, Ahmet Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin |
title | Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin |
title_full | Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin |
title_fullStr | Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin |
title_full_unstemmed | Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin |
title_short | Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin |
title_sort | erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin |
topic | Drug Watch |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900010/ https://www.ncbi.nlm.nih.gov/pubmed/27298507 http://dx.doi.org/10.4103/0253-7613.182887 |
work_keys_str_mv | AT akoglugulsen erlotinibinducedpurpuricpapulopustulareruptiontreatedwithpulsedazithromycin AT yavuzsibelorhun erlotinibinducedpurpuricpapulopustulareruptiontreatedwithpulsedazithromycin AT metinahmet erlotinibinducedpurpuricpapulopustulareruptiontreatedwithpulsedazithromycin |